We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

68 hedge funds and large institutions have $125M invested in Viracta Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

8% more funds holding

Funds holding: 63 → 68 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

18% less capital invested

Capital invested by funds: $151M → $125M (-$26.8M)

26% less call options, than puts

Call options by funds: $497K | Put options by funds: $673K

Holders
68
Holders Change
+5
Holders Change %
+7.94%
% of All Funds
1.19%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
19
Reduced
15
Closed
8
Calls
$497K
Puts
$673K
Net Calls
-$176K
Net Calls Change
-$100K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$10.5M
2
ASP
Adams Street Partners
Illinois
+$7.19M
3
JP Morgan Chase
JP Morgan Chase
New York
+$5.56M
4
Blackstone Inc
Blackstone Inc
New York
+$2.35M
5
State Street
State Street
Massachusetts
+$920K

Top Sellers

Rank Fund Capital Flow
1
SAM
Sectoral Asset Management
Quebec, Canada
-$4.49M
2
KHCM
Kettle Hill Capital Management
New York
-$2.1M
3
B
Bailard
California
-$936K
4
Goldman Sachs
Goldman Sachs
New York
-$890K
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$630K
Name Holding Trade Value Shares
Change 		Change in
Stake
William Blair & Company
26
William Blair & Company
Illinois
$416K – – –
B
27
Bailard
California
$401K -$936K -95,000 -66%
BCM
28
Bridgeway Capital Management
Texas
$401K – – –
Franklin Resources
29
Franklin Resources
California
$350K +$430K +43,618 New
OC
30
Oppenheimer & Co
New York
$305K +$375K +38,037 New
NMC
31
NEA Management Company
Maryland
$297K – – –
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$291K +$357K +36,262 New
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$289K +$58.1K +5,894 +20%
PAI
34
Palo Alto Investors
California
$266K – – –
Morgan Stanley
35
Morgan Stanley
New York
$253K -$43.8K -4,445 -12%
LSA
36
Leonteq Securities AG
Switzerland
$245K – – –
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$177K -$88.2K -8,945 -29%
JF
38
Jump Financial
Illinois
$175K +$215K +21,852 New
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$171K -$4.9K -497 -2%
Deutsche Bank
40
Deutsche Bank
Germany
$167K -$6.61K -671 -3%
SG Americas Securities
41
SG Americas Securities
New York
$164K +$202K +20,454 New
AIG
42
American International Group
New York
$159K -$4.65K -472 -2%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$157K -$300K -30,404 -61%
BCM
44
Bourgeon Capital Management
Connecticut
$150K +$180K +18,250 +3,650%
VOYA Investment Management
45
VOYA Investment Management
Georgia
$115K – – –
H
46
HoyleCohen
California
$112K – – –
Invesco
47
Invesco
Georgia
$94K +$116K +11,735 New
TI
48
Trexquant Investment
Connecticut
$89K +$7.77K +788 +8%
Wells Fargo
49
Wells Fargo
California
$83K +$85.6K +8,688 +507%
State Board of Administration of Florida Retirement System
50
State Board of Administration of Florida Retirement System
Florida
$81K +$99.2K +10,068 New
1
2
3

VIRX Hedge Fund Activity: Q3 2021 in Review

68 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2021, worth a combined $125M — down 18% from $151M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new VIRX positions and 8 closed out — a net gain of 6 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $10.5M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $4.49M sold.

  • 68 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2021, up from 63 in Q2 2021.
  • Funds reported $125M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2021, down 18% quarter-over-quarter.
  • 14 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2021 and 8 closed out, a net change of +6 holders.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2021 was T. Rowe Price Associates, an estimated $10.5M added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2021 was Sectoral Asset Management, an estimated $4.49M sold.

Based on aggregated 13F filings for Q3 2021.